Introduction
Pulmonary vein isolation (PVI) is considered to be a cornerstone of invasive therapy of paroxysmal atrial fibrillation (PAF) [1, 2] . However, numerous technologies emerged on the market during last 10 years and typical ''point-by-point'' ablation around the pulmonary vein (PV) ostia or antra was originally intended to be replaced by ''single burn'' technologies, which requires only one or a few radiofrequency (RF) or other energy applications to achieve pulmonary vein isolation, thus making the procedure more simple, shorter, safer and at the same time effective [3] [4] [5] [6] . In parallel, 3D mapping systems evolved and recently, the electrophysiologists have gained the possibility of appropriate contact force measurement [7] , a believed ''last piece in the puzzle'' tool to achieve durable electrical disconnection of the PVs, remote catheter navigation or real-time visualization of all catheters within the heart chamber. The precipitous testing of these new technologies, which can be thoroughly documented in the field of RF ablation for PAF during last few years [8] , poses inherent risk of non-validated use, as one technology is rapidly replaced by the other with no prove of superiority and/or non-inferiority with all potential consequences. The purpose of this article is to summarize experience of an expert single center with PVI using four different technologies. Rather than randomized comparison, we would like to provide consecutive cohort assessment in this analysis, with stress to the risks and benefits both for the patients and for the operators.
Methods

Patients and procedure
We partially retrospectively and mainly prospectively analyzed four groups of consecutive patients treated at our clinic between 2009 and 2011, who underwent catheter treatment for PAF with respect to the used technology and clinical results:
(1) Patients treated with conventional ''point-by-point'' manual ablation using old generation 3D mapping system CARTO XP (Biosense Webster Inc., Diamond Bar, CA, USA)-group A. AF was considered paroxysmal if patients had a history of recurrent, self-terminating episodes of arrhythmia spontaneously converted to normal SR or either electrically of pharmacologically cardioverted within 48 h if the symptoms were severe. Patients without structural heart disease were not required to test antiarrhythmic drugs prior to the procedure. Patients with persistent AF were excluded from this study as well as patients with significant structural abnormalities (left atrial (LA) dimensionZ50 mm, left ventricular ejection fraction (LVEF)r50%, valvular insufficiency and/or stenosisZgrade 3, hypertrophic cardiomyopathy with septal thicknessZ20 mm). Transoesophageal echocardiography was performed 1 day prior to procedure to exclude LA thrombus.
CT imaging
Anatomy of the LA and PVs is known to be highly individual and variable. A 64-slice CT scan (Aquilion TM 64 TSX-101 A, Toshiba) was performed on the day prior to the ablation procedure, with subsequent 3D reconstruction of the anatomy using the CARTO MERGE TM or CARTO3 TM software (Biosense Webster Inc., Diamond Bar, CA, USA) software to ensure that all PVs were targeted for ablation.
2.3.
Ablation procedure
All procedures were done under conscious sedation using fentanyl or combination of fentanyl and diazepam. Heparin was given after accessing the LA in a loading dose of 100 IU/ kg and continuous infusion with the target ACT between 280 and 330 s. Oral anticoagulation (coumadin) was restarted in all patients directly after the procedure, using low-molecular weight heparin for bridging until INR exceeded 2.0. During procedures using CARTO XP or CARTO3 systems PV antra were targeted by contiguous focal lesions deployed at a distance45 mm from the ostia of the PVs, creating a circumferential line around both ipsilateral veins (Fig. 1) A detailed description of PVAC ablation procedure was described in details elsewhere [9] . In brief, after successful transseptal puncture the PVAC catheter was introduced to the LA via a 9 F steerable transseptal sheath (Channel, BARD Electrophysiology, Lowell, MA, USA) (Fig. 2) . The standard ablation setting was 4:1 bipolar to unipolar RF energy application during 60 s, with a power limit of 8 W and target temperature of 60 1C. Overlapping applications were performed until the local antral voltage abated (Fig. 3) . PVI with entrance block was verified by mapping inside each vein using PVAC and finally at the end of the procedure using conventional circular mapping catheter (LASSO s , Biosense Webster Inc., Diamond Bar, CA, USA) showing absence of local PV potentials during sinus rhythm or pacing from the coronary sinus and/or left atrial appendage, when appropriate.
The PVI in the Hansen group was made in a similar fashion as in the CARTO groups with following differences: (1). Reconstruction of the LA was performed using EnsiteNavX navigation system (St. Jude Medical, St. Paul, MN, USA). (2) 
Follow-up
Three month blanking period to allow for tissue healing and lesion consolidation was planned and any recurrence of AF during this period was not considered failure of treatment.
Patients were advised to continue their antiarrhythmic therapy that had proven to be previously ineffective, during this blanking period. After one month, the first 7-day Holter was performed, and if no arrhythmia recurrence was detected, discontinuation of all antiarrhythmic drugs was advised. Further 7-day Holters were performed every 3 months after the procedure until the 24th month following the index procedure. Documented episodes of AF lasting 460 s on any of these three 7-day Holters were considered a failure of treatment. In addition, if patients felt palpitations and no arrhythmias were detected on the 7-day Holter, monitoring of the heart rhythm was done using a patient-activated, simple to use Holter device taking down a one minute ECG recording during symptoms. Patients remained on oral anticoagulation therapy with vitamin K antagonists with the target INR 2.5-3.0 throughout the whole study if the CHADS 2 (or later CHA 2 DS 2 VASc) was Z2. In patients with lower CHADS 2 score the anticoagulation therapy was discontinued after 6 months following the index procedure if no arrhythmia was detected both at the 3rd and 6th month of the follow-up.
Statistical analysis
Statistical analysis was performed using MedCalc software, ver. 12. 
Results
Number of patients in group A, B, C and D and their baseline clinical characteristics are listed in Table 1 . The patients in all four groups did not differ with respect to age, gender, concomitant diseases, antiarrhythmic therapy, that was proved to be ineffective prior to invasive procedure, and both left ventricular ejection fraction and left atrial diameter.
Procedural outcome
Procedural characteristics are shown in Table 2 . Upgrading from CARTO XP (Group A) to any other technology (CARTO3, PVAC and Hansen, groups B, C and D, respectively), significantly shortened both total procedural time and X-ray time (po0.001 for all). Moreover, using PVAC catheter for PVI was connected with significant shortening of procedural time when compared to any other technology (po0.001 for all). There was no difference in procedural and fluoroscopic times detected between manual and robotic approach provided that manual approach was performed using CARTO3 electromagnetic mapping system, however, a trend towards shorter procedural time appeared using manual approach (p ¼0.06).
Fluoroscopic time was significantly longer in CARTO XP group when compared to any other technology (po0.0001 for all). Both CARTO3 and robotic group had shorter X-ray times than PVAC group (po0.0001). Length of in-hospital stay did not differ between the groups. Acute success of PV isolation was also comparable between all patient groups. Total RF time applied necessary to achieve all PVI was significantly longer in Group A (CARTO XP) when compared to any other technology (po0.001 for all).
In total 312 patients treated for PAF only one serious complication was noted. The complication was linked with the introduction of the robotic sheath (Artisan) in the Group D. Due to extreme tortuosity of the right iliac vein this vein was disrupted and continuous leakage of the blood to the pelvic interstitium was proved by injecting contrast agent to the femoral vein. Subsequently, the procedure had to be prematurely stopped and extravasation was solved by percutaneous implantation of a wall-graft in the torn area without any permanent sequellae. There was a higher cumulative incidence of minor local vascular complications (AV fistula, pseudoanerysm, large hematoma, thrombosis and infection) in the CARTO XP group of patients when compared to other patient groups (p ¼0.02). All minor complications did not require any surgical intervention and was solved either by manual compression under sonographic guidance (AV fistulas, pseudoanerysms) or by local and/or systemic antibiotic administration (groin infection).
Clinical outcome
Arrhythmia free survival defined as absence of any supraventricular arrhythmia (both atrial tachycardia and fibrillation and Sensei) at 12th month (75% vs. 76.1%, p¼ NS). Arrhythmia free survival did not differ between groups A and C (i.e. CARTO XP and PVAC) either, both at 12th and 24th month of follow-up (68.7% vs. 65.8%, p¼ NS, and 55.5% vs. 58.2%, p¼ NS, respectively). Both robotic and CARTO3 groups had significantly better arrhythmia-free survival than CARTO XP and PVAC groups (log rank po0.01 for all). No minor or major late complications (beyond 30 days following the index procedure) were noted in any of the groups.
Discussion
The main result of our comparative study is that upgrading to novel technologies used during PVI can bring significant improvement in several aspects. First, the workflow of the electrophysiology lab can be accelerated by shortening total procedural time of AF ablation. Dramatic improvement was noted especially with an introduction of duty-cycled RF ablation with PVAC system. Entire duration of the procedure was almost halved. By simultaneously applying RF energy to virtually whole circumference of the PV antra it is possible to achieve complete electrical isolation just by a few one minute lasting burns. In our previous study we reported median of 6, 5, 4 and 4 burns needed for the disconnection of the left upper, left lower, right upper and right lower pulmonary vein, respectively [9] , in line with other reports [5] . Also duration of PVI procedures using PVAC catheter in our center is in concordance with previous results described by other experienced centers using this technology [5, 10, 11] .
Both CARTO3 mapping system and Sensei robotic technology also made ablation procedures much quicker, albeit not to such as an extent as PVAC catheter.
Second, the fluoroscopic times during AF ablations are of a growing importance, especially in high-volume centers. Recent multicenter Italian study showed significant decrease in mean fluoroscopy time exposure comparing catheter treatment of AF using older CARTO XP system and new generation CARTO3, resulting in shortening of radiation exposure time almost to a half (26715.1 min to 15.9712.3 min, po0.001) [12] . We currently perform about 300 RF ablations for AF or complex supraventricular arrhythmias per year in our center (only two operating physicians). If a technology is able to save in average 17 min of X-ray time per procedure, as it was seen in our comparative study (CARTO3 vs. CARTO XP), the cumulative fluoroscopic time spared would reach hardly believable 85 h per year! Such a dramatic decline of radiation exposure is even pronounced during robotic ablations. While total X-ray time during Sensei cases is comparable to manual ablations using CARTO3, the absence of the operator in the operating theater during PV isolation itself leads to further reduction of X-ray exposure, as the operator is present in the lab only during catheter introduction, transseptal puncture and LA geometry creation (preparatory phase of the procedure). Our previous study showed that in such cases the mean X-ray exposure during robotic ablations of PAF can be reduced down to 5.671.6 min [13] .
Other ''single shot'' devices have been recently tested for PV isolation in patients with PAF. In the cryoablation balloon study, however, the total procedural time increased to 2117108 min with excessive fluoroscopy times of 52736 min [14] . Recent systematic review of published studies on cryoablation technology, which pooled results of 23 trials, proved average procedural time 206772 min (range 108-371 min), with fluoroscopy time of 46713 min (range 20.1-84.5 min) [15] . Thus, even the shortest Xray time during cryoablation of PVs (about 20 min) is at least twice longer than mean time during ''point-by-point'' ablation using CARTO3 or robotic technology, and the procedure itself is prolonged by 60-70 min in average. Another technology, that was approved for PV isolation, but never got widely spread c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 9 3 -e 4 0 0 mainly due to technical reasons and low clinical success rate [16] , was high-density mesh ablation/mapping catheter (Bard, Lowell, MA, USA). Steinwender et al. reported procedural times reaching 187736 min and fluoroscopic times 34710 min when using this high-density mesh ablation [3] . Thus, based on the published data and our results, the multipolar circular catheter PVAC seems to be the only technology for PV isolation that fulfils the expectations regarding shortening of an otherwise lengthy procedure, together with reducing radiation exposure.
Recently, several safety issues regarding silent cerebral microembolism (SCM) during RF ablation for AF have been raised [17, 18] . Silent cerebral embolism is occlusion of a blood vessel in the brain due to an embolus that does not result in any acute clinical symptoms, i.e. it is ''silent''. During an AF ablation procedure, emboli may occur as a result of catheter manipulation, sheath materials, anticoagulation levels, air introduction during sheath/catheter introduction and/or as a result of the ablation process [19, 20] . Recent studies showed, that phased RF energy using PVAC system led to significant increase of SCM detected during diffusion weighted magnetic resonance imaging (DW-MRI) when compared to irrigated RF energy and cryoballoon (38.9% vs. 8.3% and 5.6%, respectively) [17] . However, SCM has also been observed following most of invasive cardiac procedures like cardiac valve replacement (47%), by-pass grafting (34%), coronary angiography (15%), carotid artery stenting (30%) and others [21] . Kruis et al. performed independent review of 22 cardiac surgery trials from the past 3 decades and showed that 66% of studies reviewed showed no associations between SCM and risk of cognitive decline, while 34% did [22] . The authors concluded that based on the review of published studies they could not confirm any association between microemboli and postoperative cognitive decline. Furthermore, there is no association between neurological symptoms and the presence of post procedural acute cerebral lesions in any of the published studies with AF ablation. Such a link would be difficult to find, as even with cardiac surgery procedures conducted over last 30 years, no association has been established between cerebral microemboli and post-operative cognitive decline.
All four groups in our study seemed to be comparable with respect to overall complication rate. There was no difference in occurrence of major adverse clinical events like tamponade, atrio-esophageal fistula, gastroparesis, phrenic nerve palsy, embolic complications and death between the groups, as no such complication happened in our cohort of patients. We observed one serious complication during Artisan introduction, which was finally fixed by wall-stent implantation into the iliac vein without any permanent consequences. Therefore, we strongly advise very careful introduction of the robotic sheath under continuous fluoroscopic control. The best technique may be to introduce cool-tip ablation catheter into the Artisan sheath as far as possible, bend it in the vasculature, keep the close loop of the ablation catheter so that the tip of catheter points always backwards and push it together with the Artisan forward while maneuvering with the ablation catheter handle until the right atrium is reached. The use of longer 14 F sheaths for Artisan introduction may be also beneficial, especially in obese patients.
Significantly higher incidence of local vascular complications in the CARTO XP group could be explained by our former practice to introduce a 4 F sheath in the left femoral artery for invasive blood pressure measurement. After several such complications we soon changed for radial artery cannulation (in fact in majority of group C patients and in almost all patients in groups B and D), which limited the incidence of AV fistulas and pseudoaneurysms close to 1%.
Third, clinically relevant observation made in our study was, that novel technologies are capable of improving arrhythmia-free survival. We are awaiting long-term data from our hospital registries, but AF-free survival without antiarrhythmic drugs was improved by 10% in absolute number with novel technologies like robotic ablations or contemporary 3D mapping systems, at least at 12 months following the index procedure. Recent advantages in contact force measurement may be potent enough to ensure durable PV electrical disconnection by enabling to create transmural and continuous lesions and may increase clinical success rate.
Conclusion
The use of novel ablation technologies during pulmonary vein isolation for paroxysmal atrial fibrillation significantly reduces total procedural and fluoroscopic times whilst achieving better clinical efficacy when compared to procedures supported by older generation of mapping systems. The safety profile of novel technologies seems to be comparable.
